BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Montelukast (Singulair) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Montelukast (Singulair)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06747130-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Montelukast (Singulair): Phase 2/3 readout est. (NCT06747130)
DESCRIPTION:Montelukast (Singulair)\, phase 2/3.\nStudy: Efficacy of Montel
 ukast in Preventing Transaminase Elevation in Adult Dengue Patients\nEstim
 ated primary completion: January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/montelukast-singulair#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06747130
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07532993-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Montelukast (Singulair): Phase 4 readout est. (NCT07532993)
DESCRIPTION:Montelukast (Singulair)\, phase 4.\nStudy: Comparison of Antihi
 stamine and Antileukotriene Add-On Therapy to Intranasal Corticosteroid in
  Allergic Rhinitis\nEstimated primary completion: February 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/montelukast-singulair#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07532993
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498116-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Montelukast (Singulair): Phase 4 readout est. (NCT05498116)
DESCRIPTION:Montelukast (Singulair)\, phase 4.\nStudy: Effect of Montelukas
 t on Kidney and Vascular Function in Type 1 Diabetes\nEstimated primary co
 mpletion: February 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/montelukast-singulair#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05498116
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07320625-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Montelukast (Singulair): Phase 3 readout est. (NCT07320625)
DESCRIPTION:Montelukast (Singulair)\, phase 3.\nStudy: Efficacy of Monteluk
 ast on STEMl Patients\nEstimated primary completion: 1 February 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/montelukast-singulair#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0732062
 5
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537868-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Montelukast (Singulair): Phase 2 readout est. (NCT07537868)
DESCRIPTION:Montelukast (Singulair)\, phase 2.\nStudy: Effect of Montelukas
 t on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocar
 dial Infarction\nEstimated primary completion: May 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/montelukast-singulair#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07537868
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04572256-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Montelukast (Singulair): Phase 1 readout est. (NCT04572256)
DESCRIPTION:Montelukast (Singulair)\, phase 1.\nStudy: MOntelukast as a Pot
 ential CHondroprotective Treatment Following Anterior Cruciate Ligament Re
 construction (MOCHA Trial)\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/montelukast-singulair#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04572256
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101640-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Montelukast (Singulair): Phase 1/2 readout est. (NCT07101640)
DESCRIPTION:Montelukast (Singulair)\, phase 1/2.\nStudy: PK\, Safety and Pr
 eliminary Efficacy Study of Montelukast in Critically Ill Infants With Dev
 eloping Bronchopulmonary Dysplasia\nEstimated primary completion: 1 June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/montelukast-sing
 ulair#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07101640
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922761-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Montelukast (Singulair): Phase 2 readout est. (NCT05922761)
DESCRIPTION:Montelukast (Singulair)\, phase 2.\nStudy: BElumosudil for Bron
 chiolitis Obliterans Prevention/Therapy (BEBOP)\nEstimated primary complet
 ion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mo
 ntelukast-singulair#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05922761
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05992311-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Montelukast (Singulair): Phase 1 readout est. (NCT05992311)
DESCRIPTION:Montelukast (Singulair)\, phase 1.\nStudy: Clinical Evaluation 
 of Montelukast in Veterans With Gulf War Illness\nEstimated primary comple
 tion: April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mon
 telukast-singulair#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05992311
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07409714-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Montelukast (Singulair): Phase 1 readout est. (NCT07409714)
DESCRIPTION:Montelukast (Singulair)\, phase 1.\nStudy: SMART 2D: Study of M
 ontelukast's Effects on Renal and Cardiovascular Health in Adolescents and
  Young Adults With Type 2 Diabetes\nEstimated primary completion: December
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/montelukast-si
 ngulair#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07409714
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685886-4366@assetmemo.bio
DTSTAMP:20261121T005022Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Montelukast (Singulair): Phase 4 readout est. (NCT07685886)
DESCRIPTION:Montelukast (Singulair)\, phase 4.\nStudy: MIRACLE-T2D Monteluk
 ast Intervention for Renal\, Cardiovascular and Eye Health in Type 2 Diabe
 tes\nEstimated primary completion: 30 June 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/montelukast-singulair#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07685886
URL:https://assetmemo.bio/drug/montelukast-singulair#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
